CA3243493A1 - INTERLEUKIN-2 MUTEINS FOR THE TREATMENT OF AUTOIMMUNE DISEASES - Google Patents
INTERLEUKIN-2 MUTEINS FOR THE TREATMENT OF AUTOIMMUNE DISEASESInfo
- Publication number
- CA3243493A1 CA3243493A1 CA3243493A CA3243493A CA3243493A1 CA 3243493 A1 CA3243493 A1 CA 3243493A1 CA 3243493 A CA3243493 A CA 3243493A CA 3243493 A CA3243493 A CA 3243493A CA 3243493 A1 CA3243493 A1 CA 3243493A1
- Authority
- CA
- Canada
- Prior art keywords
- fold
- amino acid
- seq
- agent
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263309293P | 2022-02-11 | 2022-02-11 | |
| US63/309,293 | 2022-02-11 | ||
| PCT/US2023/062395 WO2023154870A1 (en) | 2022-02-11 | 2023-02-10 | Interleukin-2 muteins for the treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3243493A1 true CA3243493A1 (en) | 2023-08-17 |
Family
ID=85476118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3243493A Pending CA3243493A1 (en) | 2022-02-11 | 2023-02-10 | INTERLEUKIN-2 MUTEINS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230390360A1 (https=) |
| EP (1) | EP4475875A1 (https=) |
| JP (1) | JP2025506173A (https=) |
| KR (1) | KR20240148001A (https=) |
| CN (2) | CN119013034A (https=) |
| AU (1) | AU2023219773A1 (https=) |
| CA (1) | CA3243493A1 (https=) |
| MX (1) | MX2024009868A (https=) |
| TW (1) | TW202400218A (https=) |
| WO (1) | WO2023154870A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| US12098178B2 (en) | 2020-12-04 | 2024-09-24 | Visterra, Inc. | Methods of using interleukin-2 agents |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170510A (es) * | 2015-04-10 | 2018-02-26 | Amgen Inc | Muteínas de interuquina 2 para la expansión de células t regulatorias |
| US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| HRP20260151T1 (hr) | 2016-08-02 | 2026-03-27 | Visterra, Inc. | Modificirani polipeptidi i njihova uporaba |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
-
2023
- 2023-02-10 CA CA3243493A patent/CA3243493A1/en active Pending
- 2023-02-10 KR KR1020247030225A patent/KR20240148001A/ko active Pending
- 2023-02-10 EP EP23709093.1A patent/EP4475875A1/en active Pending
- 2023-02-10 CN CN202380019852.2A patent/CN119013034A/zh active Pending
- 2023-02-10 TW TW112104789A patent/TW202400218A/zh unknown
- 2023-02-10 WO PCT/US2023/062395 patent/WO2023154870A1/en not_active Ceased
- 2023-02-10 AU AU2023219773A patent/AU2023219773A1/en active Pending
- 2023-02-10 MX MX2024009868A patent/MX2024009868A/es unknown
- 2023-02-10 US US18/167,529 patent/US20230390360A1/en active Pending
- 2023-02-10 JP JP2024547537A patent/JP2025506173A/ja active Pending
- 2023-02-10 CN CN202510423645.4A patent/CN120346304A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN120346304A (zh) | 2025-07-22 |
| KR20240148001A (ko) | 2024-10-10 |
| AU2023219773A1 (en) | 2024-08-01 |
| US20230390360A1 (en) | 2023-12-07 |
| WO2023154870A1 (en) | 2023-08-17 |
| MX2024009868A (es) | 2024-08-20 |
| JP2025506173A (ja) | 2025-03-07 |
| TW202400218A (zh) | 2024-01-01 |
| EP4475875A1 (en) | 2024-12-18 |
| CN119013034A (zh) | 2024-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7483857B2 (ja) | インターロイキン－２作用物質およびその使用 | |
| US20240325554A1 (en) | Methods for treating cancer | |
| US20220226442A1 (en) | Interleukin-2 agents and uses thereof | |
| US12098178B2 (en) | Methods of using interleukin-2 agents | |
| CA3243493A1 (en) | INTERLEUKIN-2 MUTEINS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| HK40124714A (zh) | 用於治疗自身免疫性疾病的白细胞介素-2突变蛋白 | |
| HK40113125A (zh) | 用於治疗自身免疫性疾病的白细胞介素-2突变蛋白 | |
| HK40098728A (zh) | 白介素-2突变体及其用途 | |
| EA049020B1 (ru) | Средства на основе интерлейкина-2 и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240730 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240731 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240731 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240911 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240911 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241002 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20241104 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241104 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20241107 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250103 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250103 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250103 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250804 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250804 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260113 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260113 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260312 |